Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00079183 · ClinicalTrials.gov registry record · Phase 2
Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00079183 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 44 participants.
The verdict
NCT00079183, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects and how well sirolimus works as secondary therapy in treating patients with chronic graft-versus-host disease (GVHD) that did not respond to prior treatment. Sirolimus may be an effective treatment for chronic GVHD
Interventions
- DRUG sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2002-04 |
| Est. Completion | 2010-06-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00079183
The ClinicalTrials.gov registry entry for NCT00079183 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sirolimus is the first listed.
NCT00079183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00079183 about?
NCT00079183 is a clinical study titled "Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment". This phase II trial studies the side effects and how well sirolimus works as secondary therapy in treating patients with chronic graft-versus-host disease (GVHD) that did not respond to prior treatment. Sirolimus may be an effective treatment for chronic GVHD
What is the current status of trial NCT00079183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2002-04. Estimated completion is 2010-06-10.
What interventions are being tested in trial NCT00079183?
The interventions under investigation include: sirolimus (DRUG).
Who is sponsoring clinical trial NCT00079183?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.